Canopy Growth Corporation (CGC) reported a fourth-quarter loss of 17 cents per share, exceeding the Zacks Consensus Estimate of a loss of 6 cents, and revenues of $51.9 million, falling short of the expected $53.3 million, marking a 2.5% miss. The company emphasized that fiscal 2026 served as a reset year with a focus on a streamlined cost structure and a stronger balance sheet, ending the fiscal year with C$364.7 million in cash and a net cash position of C$131.3 million, compared to net debt of C$172.6 million a year earlier.
Canopy’s net revenues for the fourth quarter rose by 10% year over year to C$71.2 million, with cannabis revenues up 20% to C$54.5 million. Key areas of growth included Canada medical revenues, which grew 27% to C$25.3 million, and international cannabis revenues that soared by 68% to C$8.6 million. In terms of synergy, the integration of the MTL Cannabis acquisition is expected to yield C$10 million in annualized cost savings.
Looking ahead, Canopy aims for net revenue growth and improved gross margin in fiscal 2027, targeting key markets such as Canadian medical and European cannabis, while warning of potential revenue challenges due to changes in Veterans Affairs reimbursement in Canada.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
